Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.

@article{Tran2017CostEO,
  title={Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.},
  author={Arthur-Quan Tran and Daniel O Erim and Stephanie A. Sullivan and Ashley Lynn Cole and Emma Longley Barber and Kenneth H Kim and Paola Alvarez Gehrig and Stephanie B. Wheeler},
  journal={Gynecologic oncology},
  year={2017},
  volume={148 2},
  pages={
          329-335
        }
}
OBJECTIVE Advanced stage epithelial ovarian cancer (AEOC) can be treated with either neoadjuvant chemotherapy (NACT) or primary cytoreductive surgery (PCS). Although randomized controlled trials show that NACT is non-inferior in overall survival compared to PCS, there may be improvement in short-term morbidity. We sought to investigate the cost-effectiveness of NACT relative to PCS for AEOC from the US Medicare perspective. METHODS A cost-effectiveness analysis using a Markov model with a 7… CONTINUE READING
BETA
1
Twitter Mention